AAV transduction of dopamine neurons with constitutively active rheb protects from neurodegeneration and mediates axon regrowth

Molecular Therapy

Volumn 20, Issue 2, 2012, Pages 275-286

  Kim, Sang Ryong ^a   Kareva, Tatyana ^a   Yarygina, Olga ^a   Kholodilov, Nikolai ^a   Burke, Robert E ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OXIDOPAMINE; PARVOVIRUS VECTOR; RHEB PROTEIN;

ADENO ASSOCIATED VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DAMAGE; CELL POPULATION; CELL PROTECTION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; INTRACELLULAR SIGNALING; MALE; MOUSE; NERVE DEGENERATION; NERVE FIBER GROWTH; NERVE PROJECTION; NEUROPROTECTION; NEUROTROPISM; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; VIRAL GENE DELIVERY SYSTEM;

MAMMALIA; MUS;

EID: 84856523917     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.213     Document Type: Article

References (51)

1. Levi-Montalcini, R (1987). The nerve growth factor 35 years later. Science 237: 1154-1162. (Pubitemid 17124912)
2. Thoenen, H and Sendtner, M (2002). Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches. Nat Neurosci 5 Suppl: 1046-1050. (Pubitemid 35247196)
3. Kirik, D, Georgievska, B and Bjklund, A (2004). Localized striatal delivery of GDNF as a treatment for Parkinson disease. Nat Neurosci 7: 105-110. (Pubitemid 38129784)
4. Lin, LF, Doherty, DH, Lile, JD, Bektesh, S and Collins, F (1993). GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260: 1130-1132. (Pubitemid 23186789)
5. Choi-Lundberg, DL, Lin, Q, Chang, YN, Chiang, YL, Hay, CM, Mohajeri, H et al. (1997). Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 275: 838-841. (Pubitemid 27074886)
6. Choi-Lundberg, DL, Lin, Q, Chang, YN, Chiang, YL, Hay, CM, Mohajeri, H et al. (1997). Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 275: 838-841. (Pubitemid 27074886)
7. Rosenblad, C, Martinez-Serrano, A and Bjklund, A (1998). Intrastriatal glial cell linederived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease. Neuroscience 82: 129-137.
8. Kordower, JH, Emborg, ME, Bloch, J, Ma, SY, Chu, Y, Leventhal, L et al. (2000). Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290: 767-773.
9. Gill, SS, Patel, NK, Hotton, GR, O'Sullivan, K, McCarter, R, Bunnage, M et al. (2003). Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 9: 589-595. (Pubitemid 36597106)
10. Lang, AE, Gill, S, Patel, NK, Lozano, A, Nutt, JG, Penn, R et al. (2006). Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 59: 459-466. (Pubitemid 43358066)
11. Sherer, TB, Fiske, BK, Svendsen, CN, Lang, AE and Langston, JW (2006). Crossroads in GDNF therapy for Parkinson's disease. Mov Disord 21: 136-141.
12. Airaksinen, MS and Saarma, M (2002). The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 3: 383-394. (Pubitemid 135706635)
13. Pong, K, Xu, RY, Baron, WF, Louis, JC and Beck, KD (1998). Inhibition of phosphatidylinositol 3-kinase activity blocks cellular differentiation mediated by glial cell line-derived neurotrophic factor in dopaminergic neurons. J Neurochem 71: 1912-1919. (Pubitemid 28491546)
14. Soler, RM, Dolcet, X, Encinas, M, Egea, J, Bayascas, JR and Comella, JX (1999). Receptors of the glial cell line-derived neurotrophic factor family of neurotrophic factors signal cell survival through the phosphatidylinositol 3-kinase pathway in spinal cord motoneurons. J Neurosci 19: 9160-9169. (Pubitemid 30228068)
15. Encinas, M, Tansey, MG, Tsui-Pierchala, BA, Comella, JX, Milbrandt, J and Johnson, EM Jr (2001). c-Src is required for glial cell line-derived neurotrophic factor (GDNF) family ligand-mediated neuronal survival via a phosphatidylinositol-3 kinase (PI-3K)-dependent pathway. J Neurosci 21: 1464-1472. (Pubitemid 32182188)
16. Ugarte, SD, Lin, E, Klann, E, Zigmond, MJ and Perez, RG (2003). Effects of GDNF on 6-OHDA-induced death in a dopaminergic cell line: modulation by inhibitors of PI3 kinase and MEK. J Neurosci Res 73: 105-112. (Pubitemid 36791375)
17. Ries, V, Henchcliffe, C, Kareva, T, Rzhetskaya, M, Bland, R, During, MJ et al. (2006). Oncoprotein Akt/PKB induces trophic effects in murine models of Parkinson's disease. Proc Natl Acad Sci USA 103: 18757-18762. (Pubitemid 44913483)
18. Cheng, HC, Kim, SR, Oo, TF, Kareva, T, Yarygina, O, Rzhetskaya, M et al. (2011). Akt suppresses retrograde degeneration of dopaminergic axons by inhibition of macroautophagy. J Neurosci 31: 2125-2135.
19. Kaplitt, MG, Feigin, A, Tang, C, Fitzsimons, HL, Mattis, P, Lawlor, PA et al. (2007). Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369: 2097-2105. (Pubitemid 46935946)
20. Cheng, HC, Ulane, CM and Burke, RE (2010). Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol 67: 715-725.
21. Choi, YJ, Di Nardo, A, Kramvis, I, Meikle, L, Kwiatkowski, DJ, Sahin, M et al. (2008). Tuberous sclerosis complex proteins control axon formation. Genes Dev 22: 2485-2495.
22. Campbell, DS and Holt, CE (2001). Chemotropic responses of retinal growth cones mediated by rapid local protein synthesis and degradation. Neuron 32: 1013-1026. (Pubitemid 34075393)
23. Read, DE and Gorman, AM (2009). Involvement of Akt in neurite outgrowth. Cell Mol Life Sci 66: 2975-2984.
24. Park, KK, Liu, K, Hu, Y, Kanter, JL and He, Z (2010). PTEN/mTOR and axon regeneration. Exp Neurol 223: 45-50.
25. Avruch, J, Long, X, Lin, Y, Ortiz-Vega, S, Rapley, J, Papageorgiou, A et al. (2009). Activation of mTORC1 in two steps: Rheb-GTP activation of catalytic function and increased binding of substrates to raptor. Biochem Soc Trans 37(Pt 1): 223-226.
26. Urano, J, Comiso, MJ, Guo, L, Aspuria, PJ, Deniskin, R, Tabancay, AP Jr et al. (2005). Identification of novel single amino acid changes that result in hyperactivation of the unique GTPase, Rheb, in fission yeast. Mol Microbiol 58: 1074-1086. (Pubitemid 41667226)
27. Yan, L, Findlay, GM, Jones, R, Procter, J, Cao, Y and Lamb, RF (2006). Hyperactivation of mammalian target of rapamycin (mTOR) signaling by a gain-of-function mutant of the Rheb GTPase. J Biol Chem 281: 19793-19797. (Pubitemid 44065753)
28. Sato, T, Umetsu, A and Tamanoi, F (2008). Characterization of the Rheb-mTOR signaling pathway in mammalian cells: constitutive active mutants of Rheb and mTOR. Meth Enzymol 438: 307-320.
29. Urano, J, Sato, T, Matsuo, T, Otsubo, Y, Yamamoto, M and Tamanoi, F (2007). Point mutations in TOR confer Rheb-independent growth in fission yeast and nutrientindependent mammalian TOR signaling in mammalian cells. Proc Natl Acad Sci USA 104: 3514-3519. (Pubitemid 46364190)
30. Sauer, H and Oertel, WH (1994). Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 59: 401-415. (Pubitemid 24098798)
31. Ries, V, Silva, RM, Oo, TF, Cheng, HC, Rzhetskaya, M, Kholodilov, N et al. (2008). JNK2 and JNK3 combined are essential for apoptosis in dopamine neurons of the substantia nigra, but are not required for axon degeneration. J Neurochem 107: 1578-1588.
32. Kim, SR, Chen, X, Oo, TF, Kareva, T, Yarygina, O, Wang Cet al. (2011). Dopaminergic pathway reconstruction by Akt/Rheb-induced axon regeneration. Ann Neurol 70: 110-120.
33. Fearnley, JM and Lees, AJ (1991). Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114 (Pt 5): 2283-2301.
34. Pycock, CJ (1980). Turning behaviour in animals. Neuroscience 5: 461-514. (Pubitemid 10131221)
35. Silva, RM, Ries, V, Oo, TF, Yarygina, O, Jackson-Lewis, V, Ryu, EJ et al. (2005). CHOP/GADD153 is a mediator of apoptotic death in substantia nigra dopamine neurons in an in vivo neurotoxin model of parkinsonism. J Neurochem 95: 974-986. (Pubitemid 41713483)
36. Marẗ MJ, Saura, J, Burke, RE, Jackson-Lewis, V, JiMez, A, Bonastre, M et al. (2002). Striatal 6-hydroxydopamine induces apoptosis of nigral neurons in the adult rat. Brain Res 958: 185-191. (Pubitemid 35441227)
37. Chen, X, Rzhetskaya, M, Kareva, T, Bland, R, During, MJ, Tank, AW et al. (2008). Antiapoptotic and trophic effects of dominant-negative forms of dual leucine zipper kinase in dopamine neurons of the substantia nigra in vivo. J Neurosci 28: 672-680. (Pubitemid 351159034)
38. Zigmond, MJ, Abercrombie, ED, Berger, TW, Grace, AA and Stricker, EM (1990). Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci 13: 290-296. (Pubitemid 20193461)
39. Martin, DE and Hall, MN (2005). The expanding TOR signaling network. Curr Opin Cell Biol 17: 158-166. (Pubitemid 40380939)
40. Dunlop, EA and Tee, AR (2009). Mammalian target of rapamycin complex 1: signalling inputs, substrates and feedback mechanisms. Cell Signal 21: 827-835.
41. Foster, KG and Fingar, DC (2010). Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. J Biol Chem 285: 14071-14077.
42. Laplante, M and Sabatini, DM (2009). mTOR signaling at a glance. J Cell Sci 122(Pt 20): 3589-3594.
43. Sarbassov, DD, Guertin, DA, Ali, SM and Sabatini, DM (2005). Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101. (Pubitemid 40262113)
44. Huang, J and Manning, BD (2008). The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J 412: 179-190. (Pubitemid 351758225)
45. Huang, J and Manning, BD (2009). A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans 37(Pt 1): 217-222.
46. Datta, SR, Brunet, A and Greenberg, ME (1999). Cellular survival: a play in three Akts. Genes Dev 13: 2905-2927.
47. Downward, J (2004). PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol 15: 177-182. (Pubitemid 38251646)
48. Burke, RE (2008). Programmed cell death and new discoveries in the genetics of parkinsonism. J Neurochem 104: 875-890. (Pubitemid 351143657)
49. Li, S, Takasu, T, Perlman, DM, Peterson, MS, Burrichter, D, Avdulov, S et al. (2003). Translation factor eIF4E rescues cells from Myc-dependent apoptosis by inhibiting cytochrome c release. J Biol Chem 278: 3015-3022. (Pubitemid 36801209)
50. Przedborski, S, Levivier, M, Jiang, H, Ferreira, M, Jackson-Lewis, V, Donaldson, D et al. (1995). Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience 67: 631-647.
51. Kholodilov, N, Yarygina, O, Oo, TF, Zhang, H, Sulzer, D, Dauer, W et al. (2004). Regulation of the development of mesencephalic dopaminergic systems by the selective expression of glial cell line-derived neurotrophic factor in their targets. J Neurosci 24: 3136-3146. (Pubitemid 38405761)